A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer
Abstract
Poor prognosis of patients with muscle-invasive bladder cancer that often metastasizes drives the need for discovery of molecular determinants of bladder cancer progression. Chondroitin sulfate proteoglycans, including CD44, regulate cancer progression; however, the identity of a chondroitinase (Chase) that cleaves chondroitin sulfate from proteoglycans is unknown. HYAL-4 is an understudied gene suspected to encode a Chase, with no known biological function. We evaluated HYAL-4 expression and its role in bladder cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-2912
Entities
People
- Andre R Jordan
- Bal L. Lokeshwar
- Daley S Morera
- Diogo O. Escudero
- Ijeoma Azih
- Jiaojiao Wang
- Judith Knapp
- Kelly Hoye
- Luis E. Lopez
- Marie C. Hupe
- Martin J.p. Hennig
- Murugesan Manoharan
- Neetika Dhir
- Rohitha Baskar
- Ronny R. Racine
- Santu Ghosh
- Sarrah L Hasanali
- Soum D. Lokeshwar
- Sravan Kavuri
- Travis J. Yates
- Vinata B. Lokeshwar
- Zachary Klaassen
Organizations
- Augusta University
- National Cancer Institute
- United States Department of Defense